Biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) and partner OntoChem announced Monday the completion of the initial in silico screening process and have identified an additional specific compound, as well as multiple analogs, which could function as inhibitors of the main protease (Mpro) under the Covid-19 therapeutics programme.
Based on initial identification of the Mpro scaffold compound, the partnership has established a new in silico library of analog compounds that will be evaluated through additional in silico screening in biological assays. The project reportedly targeted the main Covid-19 virus enzyme, known as the main protease or Mpro, which plays a pivotal role in mediating viral replication.
The partnership has identified four compounds that could disrupt the function of a viral enzyme called an endoribonuclease (NSP-15). The protein Nsp 15 from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV- 2) is 89 % identical to the protein from the earlier outbreak of SARS-CoV. The candidate inhibitors of Mpro are being synthesized and then will be tested in biological assays.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review